Implications of neuroendocrine tumor and diabetes mellitus on patient outcomes and care: a matched case–control study

AIM: We aimed to determine the impact of diabetes mellitus (DM) on survival of patients with neuroendocrine tumors (NETs) and of NETs on glycemic control. PATIENTS & METHODS: Patients with newly diagnosed NETs with/without DM were matched 1:1 by age, sex and diagnosis year (2005–2017), and survi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kusne, Yael N, Kosiorek, Heidi E, Buras, Matthew R, Verona, Patricia M, Coppola, Kyle E, Rone, Kelley A, Cook, Curtiss B, Karlin, Nina J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147757/
https://www.ncbi.nlm.nih.gov/pubmed/34046189
http://dx.doi.org/10.2144/fsoa-2020-0190
Descripción
Sumario:AIM: We aimed to determine the impact of diabetes mellitus (DM) on survival of patients with neuroendocrine tumors (NETs) and of NETs on glycemic control. PATIENTS & METHODS: Patients with newly diagnosed NETs with/without DM were matched 1:1 by age, sex and diagnosis year (2005–2017), and survival compared (Kaplan–Meier and Cox proportional hazards). Mixed models compared hemoglobin A(1c) (HbA(1c)) and glucose during the year after cancer diagnosis. RESULTS: Three-year overall survival was 72% (95% CI: 60–86%) for DM patients versus 80% (95% CI: 70–92%) for non-DM patients (p = 0.82). Hazard ratio was 1.33 (95% CI: 0.56–3.16; p = 0.51); mean DM HbA(1c), 7.3%. CONCLUSION: DM did not adversely affect survival of patients with NET. NET and its treatment did not affect glycemic control.

Ejemplares similares